| Market Capitalization (Millions $) |
185 |
| Shares
Outstanding (Millions) |
71 |
| Employees |
106 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-140 |
| Cash Flow (TTM) (Millions $) |
-6 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Zentalis Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that specializes in developing small molecule drugs for the treatment of cancer. The company was founded in 2014 and is headquartered in New York City, USA.
The company's primary focus is on developing cancer therapies that target specific protein biomarkers expressed by tumor cells. Zentalis Pharmaceuticals has a proprietary drug discovery platform that it uses to identify new targets and create optimized drug candidates for clinical development.
The company's pipeline is focused on several clinically validated targets, including BCL-2 inhibitor, WEE1 kinase inhibitor and SHP2 inhibitor. The company's lead compounds are ZN-c5 and ZN-c3, which target BCL-2 and WEE1 kinases, respectively. Both of these targets have been shown to be important in the survival and proliferation of cancer cells.
Zentalis Pharmaceuticals is also developing a portfolio of SHP2 inhibitors, including ZN-449, which has shown promising results in preclinical models of cancer. SHP2 is a critical regulator of downstream signaling pathways that are commonly dysregulated in cancer, making it an attractive target for drug development.
The company has a strong team of scientific and clinical leaders with deep experience in the pharmaceutical industry. Their expertise includes oncology drug development, clinical trial design and execution, and regulatory affairs.
Overall, Zentalis Pharmaceuticals Inc. is well-positioned to advance its pipeline of cancer therapies through clinical development and ultimately commercialization. Its meaningful collaborations with leading academic research institutions and experienced team of experts, along with its cutting-edge drug discovery platform, make it an attractive partner for collaboration and investment in the fight against cancer.
Company Address: 10275 Science Center Dr. San Diego 92121 CA
Company Phone Number: 263-4333 Stock Exchange / Ticker: NASDAQ ZNTL
|
4.25%